John Libbey Eurotext

European Cytokine Network

Pulmonary artery hypertension: pertinent vasomotorial cytokines Volume 28, issue 1, March 2017

Figures

  • Figure 1
  • Figure 2
Author
Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian 351100, Fujian Province, People's Republic of China
* Correspondence: Shi-Min Yuan. Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian 351100, Fujian Province, People's Republic of China
  • Key words: cytokines, pathogenesis, pulmonary hypertension
  • DOI : 10.1684/ecn.2016.0386
  • Page(s) : 1-7
  • Published in: 2017

Pulmonary artery hypertension is a syndrome that shows similar clinical and pathophysiological features characterized by elevated pulmonary arterial pressure and resistance. There have been a series of hypotheses trying to describe the development of pulmonary artery hypertension; however, none of them perfectly explains its pathogenesis. To highlight the pathogenesis, novel vasomotorial cytokines including hypoxia-inducible factor-1α, endothelin-1, urotensin II, Krüppel-like factor 4, calcitonin gene-related peptide, angiopoietins, and serotonin closely related to pulmonary artery hypertension are discussed. The development of the new agents relating to these cytokines may improve the relevant treatment strategies.